Dados do Trabalho

Título

Primary findings from the TROMBOGLIO Study: A multicenter, prospective, and retrospective cohort investigation of adults diagnosed with CNS Malignant Neoplasms in Brazil

Objetivo

We investigated the incidence of thrombotic and hemorrhagic events in Brazilian adults with CNS malignant neoplasms.

Métodos

TROMBOGLIO Study is a cohort study involving 200 participants diagnosed between 2021-2023. Data were collected from medical records. Primary outcome was the probability of occurrence of thrombotic/hemorrhagic events, and secondary outcome was the risk of death due to these events. We performed a descriptive data analysis and calculated the rates of thrombotic/hemorrhagic events. The overall survival (OS) probability and event-free survival (EFS) were determined using the Kaplan-Meier test. Survival curves were compared using the log-rank test. Cox regression analysis was performed to investigate the risk factors (hazard ratio [HR]) associated with thrombotic/hemorrhagic events and death.

Resultados

Overall, our sample predominantly consisted of middle-aged men (n=121; 60.5%). We observed a thrombotic event ratio of 10% (55% DVT and 30% DVT/PE) and 4% (n=6) a hemorrhagic event. The EFS rates were 82.4% and 68.3% at 12 and 24 months. We did not find differences when comparing grade 3 and 4 tumors (63.6% vs. 1/2 88.2%; p=0.283; HR=1.85; CI95% 0.61–5.39), and non-mutant and mutant IDH cases (64.7% vs. 87.6%; p=0.653; HR=1.24; 95%CI 0.31–2.10). The OS rates were 76.6% and 51.7% at 12 and 24 months. The OS rate for patients who experienced thrombotic/hemorrhagic events was 55.7% compared to 77.6% in those without events (p=0.108; HR=1.81; 95%CI 0.88–3.74).

Conclusão

We did not find a significant difference in event-free survival. Having or not a thrombotic/hemorrhagic event were similar for OS.